Actinogen Medical Expects Results From XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%
Actinogen Medical Expects Results From XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%
Actinogen医疗预计将于8月公布XanaCIDD二期临床试验的结果;股价下跌6%。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册